Black F T, Gaarslev K, Orskov F, Orskov I, Stenderup A, Stenderup J, Christensen O
Scand J Infect Dis. 1983;15(2):189-93. doi: 10.3109/inf.1983.15.issue-2.11.
The efficacy of mecillinam when given orally in preventing travellers' diarrhoea has been studied. Preliminary investigations in volunteers showed that single daily doses of up to 200 mg for 3 weeks were well tolerated. A randomised double-blind study was carried out in a group of tourists visiting Egypt and the Far East. The subjects took either mecillinam (200 mg daily) or placebo for 25 days. 19/36 tourists (53%) taking placebo and 5/38 tourists (13%) taking mecillinam developed travellers' diarrhoea during the treatment period (p less than 0.001). In the placebo group enterotoxigenic Escherichia coli (LT/ST) were found in 2 cases of diarrhoea and Salmonella in another 2 cases. In the remaining cases of diarrhoea the etiological agent was not found in either of the 2 groups.
已对口服美西林预防旅行者腹泻的疗效进行了研究。对志愿者的初步调查表明，连续3周每日单次服用高达200毫克的剂量耐受性良好。在一组前往埃及和远东地区的游客中进行了一项随机双盲研究。受试者服用美西林（每日200毫克）或安慰剂，为期25天。在治疗期间，服用安慰剂的36名游客中有19名（53%）出现旅行者腹泻，服用美西林的38名游客中有5名（13%）出现旅行者腹泻（p<0.001）。在安慰剂组中，2例腹泻患者检测出产肠毒素大肠杆菌（LT/ST），另外2例检测出沙门氏菌。在其余腹泻病例中，两组均未发现病原体。
